Welcome to our dedicated page for Icu Medical SEC filings (Ticker: ICUI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ICU Medical SEC filings document the company’s medical-device operations, public-company governance and recurring financial disclosures. Form 8-K reports furnish quarterly earnings releases, including GAAP results, non-GAAP reconciliations, adjusted EBITDA, adjusted diluted earnings per share, product-line revenue and the reporting effects of the completed IV Solutions divestiture.
Proxy materials describe annual meeting matters, board and compensation governance, executive compensation and equity-award disclosures. Other current reports cover officer and compensation arrangements, including amendments to the ICU Medical Executive Severance Plan. Together, the filings record the company’s capital-market reporting obligations, governance practices and operating results for its infusion systems, consumables and critical care product categories.
ICU Medical, Inc. will hold its virtual Annual Meeting on May 13, 2026; the record date for voting is March 20, 2026 and 24,992,388 shares of Common Stock were outstanding as of that date. The Board asks shareholders to elect seven directors, ratify Deloitte & Touche LLP as auditor, approve an advisory say-on-pay, and vote on charter amendments to adopt simple majority voting and a 25% special-meeting ownership threshold, plus related adjournment and a non-binding stockholder proposal to adopt a 10% special-meeting right.
The proxy discloses executive pay design and 2025 outcomes: $2,231.3M revenue, reported Adjusted EBITDA $403.8M (final MIP result $425.0M) and Free Cash Flow reported $99.9M (final MIP result $125.0M), which funded the 2025 MIP at 150%. CEO Vivek Jain had 2025 base salary $775,000 and received performance and time-based RSUs.
ICU Medical Chief Operating Officer Christian B. Voigtlander reported compensation-related share activity tied to performance awards. He exercised performance-based restricted stock units and restricted stock units that settled into 14,648 shares of Common Stock, with no purchase or exercise price.
These units were granted on 3/15/2023 and, after the Compensation Committee certified results on 2/11/26, the performance-based awards were earned at 117% of target. To cover tax obligations, 8,096 shares were withheld at $125.85 per share, leaving a net increase of 6,552 shares. Following these transactions, Voigtlander directly owns 46,306 shares of Common Stock.
ICU Medical Inc. executive Daniel Woolson, VP and GM-Infusion Capital, exercised performance-based restricted stock units into common stock. He converted 2,924 performance shares into 2,924 shares of common stock, then had 1,295 of those shares withheld to cover tax obligations at $125.85 per share. After these compensation-related transactions, he holds 24,602 shares of common stock directly, indicating a routine vesting and tax-settlement event rather than an open‑market trade.
ICU Medical Inc. Chief Information Officer Ben Sousa reported compensation-related equity activity involving Restricted Stock Units. On 2026-03-15, 1,300 Restricted Stock Units converted into an equal number of shares of Common Stock at no purchase or exercise price. In a related step, 718 shares were withheld at $125.85 per share to satisfy tax obligations, rather than being sold on the open market. Following these transactions, Sousa directly owned 5,326 shares of ICU Medical Common Stock.
ICU Medical Inc. VP and General Counsel Virginia Ruth Sanzone reported compensation-related equity activity. On March 15, 2026, she settled performance-based restricted stock units and restricted stock units that converted into 7,324 shares of Common Stock.
To cover tax obligations, 4,047 shares were withheld at $125.85 per share, resulting in a net addition of 3,277 shares. Following these transactions, she directly holds 21,907 shares of ICU Medical common stock. The PRSUs, granted on March 15, 2023, were earned at 117% of target after performance certification.
ICU Medical (ICUI) Chairman and CEO Vivek Jain reported equity award activity and related tax withholding. On March 15, 2026, performance-based restricted stock units granted on March 15, 2023 were earned at 117% of target after Compensation Committee certification, resulting in the exercise of derivative awards for 21,972 shares of common stock. To cover tax liabilities, a total of 12,145 shares of common stock were withheld at $125.85 per share, which is not an open-market sale. Following these transactions, Jain directly holds 126,833 shares of common stock and indirectly holds 152,339 shares through a trust.
ICU Medical Chief Financial Officer Brian Michael Bonnell exercised stock awards and settled related taxes in shares. He exercised performance-based restricted stock units and restricted stock units, acquiring 14,648 shares of common stock with no cash exercise price. To cover tax liabilities, 7,595 shares were withheld at $125.85 per share, a non-market disposition. After these compensation-related transactions, he directly owns 71,750 shares of ICU Medical common stock.
ICU Medical Chief Financial Officer Brian Michael Bonnell reported equity award activity involving performance-based and time-based stock units. On March 8, 2026, performance stock units granted on March 8, 2024 were certified at 250% of target, resulting in the acquisition of 71,757 shares of common stock, with no exercise price.
On the same date, 39,667 shares of common stock were disposed of at $132.00 per share to cover tax obligations through share withholding, leaving 64,697 shares directly owned afterward. On March 7, 2026, additional equity awards were settled, including 3,522 shares acquired via derivative exercises and 1,263 shares withheld for taxes, resulting in 32,607 directly owned shares after that date.
ICU Medical Chairman and CEO Vivek Jain reported multiple equity award transactions. On March 8, 2026, he exercised 107,635 performance shares at $0.00 per share, acquiring the same number of common shares, which were earned at 250% of target PRSU performance after Compensation Committee certification.
That same day, 59,500 common shares were disposed of at $132.00 per share to satisfy tax obligations through share withholding, not an open-market sale. On March 7, 2026, he exercised awards covering 5,282 shares twice (derivative and non-derivative reporting), and 2,919 shares were withheld for taxes. Following these events, he also reported 152,339 common shares held indirectly through a trust.
ICU Medical Chief Information Officer Ben Sousa reported multiple equity award transactions. On 3/7/26 and 3/8/26, he acquired common stock through the exercise or settlement of Restricted Stock Units and performance-based Restricted Stock Units, including 7,177 performance shares earned at 250% of target following Compensation Committee certification.
On both dates, some common shares were disposed of in transactions coded “F” at a price of $132 per share, representing shares withheld to satisfy tax obligations rather than open-market sales. After these transactions, Sousa directly owned 4,744 shares of ICU Medical common stock.